Comparing TNK vs TPA for stroke in a mobile unit
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial compares two clot-busting medicines, TNK and TPA, given through an IV in a special ambulance (Mobile Stroke Unit) to treat acute ischemic stroke. The goal is to see which drug works better when started quickly after symptoms begin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are diagnosed with a stroke caused by a blood clot (ischemic stroke).
- Your stroke symptoms started less than 4.5 hours ago.
- You are older than 18 years old.
- You do not have any medical reason that prevents you from receiving a clot-busting drug (like recent bleeding or surgery).
- You are willing and able to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called rhTNK-tPA for treating acute ischemic stroke (a clot in the brain) up to 24 hours after symptom onset. The study uses simplified imaging to determine eligibility and aims to help patients recover better outcomes.
This study compares the safety of two FDA-approved clot-dissolving medicines (rhTNK-tPA and rt-PA) given through an IV to patients having an acute ischemic stroke (a stroke caused by a blood clot in the brain). Researchers want to understand which treatment is safer and how well each works.
This trial compares two clot-dissolving medications (tenecteplase and reteplase) given before a procedure to remove a large clot from a brain artery. It aims to see which drug works better for people who have had an acute ischemic stroke and are eligible for both treatments.
This trial tests a clot-dissolving medication called rhTNK-tPA for people who had a stroke 4.5 to 24 hours ago. It aims to help those with certain types of blockages in the brain who are still having moderate to severe symptoms.
This trial tests if the clot-busting drug tenecteplase is safe and effective for people having an ischemic stroke who have recently taken blood thinners (DOACs). If you qualify, you may receive either tenecteplase or a placebo within 24 hours of your last known well time.
This trial tests if a clot-busting drug called tenecteplase can improve outcomes for people with a large vessel stroke when treatment starts 4.5 to 24 hours after symptoms began, and when a mechanical clot removal procedure (EVT) is not available. You would receive tenecteplase or standard medical care to see which works better.
Hear when a new Intravenous trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.